MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas (NCT06712875)
A Pilot Study Evaluating the Toxicity and Clinical Benefit of Mitogen-activated Protein Kinase (MAPK) Pathway Inhibition Combined With Programmed Cell Death-1 Checkpoint Blockade (Anti-PD1) for the Treatment of BRAF-altered Pediatric Gliomas
🩺 Plain-English Summary (8th-Grade Level)
Pediatric gliomas harboring BRAF-alterations, commonly BRAFV600 mutation or KIAA1549-BRAF fusion, are currently treated with either chemotherapy or mitogen activated protein kinase (MAPK) inhibitors, such as, dabrafenib and/or trametinib. Unfortunately, some BRAF-altered gliomas can progress or have rebound growth after discontinuation of therapy. Data from BRAFV600E-mutant melanoma has shown potential synergy between MAPK inhibition and anti-programmed cell death 1 (anti-PD1) checkpoint blockade. Anti-PD1 therapy, such as, nivolumab can block the PD1 receptor on T cells, a marker of T cell exhaustion, allowing a continued or more robust anti-tumor immune response. Here, investigators will combine MAPK inhibition with anti-PD1 therapy in recurrent, refractory low grade BRAF-altered glioma and newly diagnosed or recurrent BRAF-altered or NF-altered high grade glioma.
Who can join: Review the eligibility criteria below.
Location: Children's National Hospital — Washington D.C., District of Columbia
Age range: 1 Year to 26 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- Children's National Hospital — Washington D.C., District of Columbia
- Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois
- Memorial Sloan Kettering Cancer Center — New York, New York
📞 Contact the Study Coordinator
Phone: (312) 227-4847
Email: mnewmark@luriechildrens.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Low Grade Glioma
- Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG) — Los Angeles, California
- Proton Radiation Therapy for Gliomas — Boston, Massachusetts
- A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma — Phoenix, Arizona
- Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma — Los Angeles, California
- A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma — Birmingham, Alabama
- Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Patients Diagnosed With a Glioma — Detroit, Michigan
Explore by condition: All Low Grade Glioma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.